For remote patient monitoring (RPM) providers, medical device distributors, and healthcare procurement teams, an FDA 510(k) clearance number is an important starting point when evaluating a pulse oximeter. However, FDA 510(k) clearance does not guarantee that a device will deliver a specific level of accuracy under every clinical condition.

FDA 510(k) K232989 covers the AOJ-70A, AOJ-70B, AOJ-70C, AOJ-70D, and AOJ-70E pulse oximeters manufactured by Shenzhen AOJ Medical Technology Co., Ltd. The FDA issued a Substantial Equivalence determination on July 1, 2024, under product code DQA and regulation 21 CFR 870.2700.

For buyers, the key question is not simply whether a device has FDA clearance. It is whether the device’s cleared intended use, supporting performance data, and technical capabilities match the requirements of the target patient population and monitoring program.

This guide explains what K232989 establishes, how to interpret the reported SpO₂ accuracy metric, and which regulatory and technical documents buyers should review before selecting a pulse oximeter for an RPM deployment.

1. What Does FDA 510(k) K232989 Actually Establish?

FDA 510(k) is a premarket notification pathway through which a manufacturer demonstrates that a device is substantially equivalent to a legally marketed predicate device. The FDA evaluates the submission and determines whether the device can be marketed under the applicable regulatory framework.

K232989 identifies five AOJ pulse oximeter models and classifies them as Class II devices under 21 CFR 870.2700.

K232989 Regulatory Overview

What Substantial Equivalence Means

Substantial equivalence means that the FDA determined the submitted device was substantially equivalent to legally marketed predicate devices for the stated indications for use. The determination considers relevant technological characteristics and supporting performance information.

However, clearance should not be interpreted as a universal guarantee of clinical outcomes, suitability for every patient group, or compliance with every requirement that may apply to a specific healthcare deployment.

Buyers should therefore review the official 510(k) Summary, indications for use, product labeling, and applicable performance evidence instead of relying on a clearance number alone.

510(k) Clearance vs. PMA Approval

The distinction between 510(k) clearance and Premarket Approval (PMA) is important during regulatory review.

These pathways serve different regulatory purposes. Neither pathway should be treated as a substitute for reviewing the actual performance requirements of the intended application.

For pulse oximeters, the FDA’s 510(k) guidance for pulse oximeter submissions provides additional context on device performance, intended use, and supporting documentation.

2. How Should Buyers Interpret the ±2% SpO₂ Accuracy Claim?

SpO₂ accuracy is a critical consideration when selecting a pulse oximeter for home healthcare or remote monitoring. However, buyers must understand the metric behind an accuracy claim before using it to compare suppliers.

The K232989 Summary reports that the device’s clinical accuracy data were referenced from the earlier K221039 submission. It describes an SpO₂ accuracy result of (A_{RMS}<2) under steady-state conditions across the 70%–100% arterial oxygen saturation range.

This is an important performance finding, but its meaning requires careful interpretation.

2.1 What Is (A_{RMS})?

(A_{RMS}) stands for root mean square accuracy, commonly used to characterize the difference between pulse oximeter readings and reference oxygen saturation measurements across a test dataset.

A simplified expression is:

[ A_{RMS}=\sqrt{\frac{1}{n}\sum_{i=1}^{n}(S_{p}O_{2,i}-S_{a}O_{2,i})^2} ]

Here:

• (S_pO_2) represents the pulse oximeter’s reading.

• (S_aO_2) represents the corresponding reference arterial oxygen saturation measurement.

• (n) represents the number of paired observations included in the calculation.

The precise test methodology and statistical treatment should follow the applicable test protocol and standard.

An (A_{RMS}<2) result does not mean every individual reading falls within ±2 percentage points of the reference value. It describes aggregate error under the evaluated conditions.

Buyers should avoid turning this statistic into a guarantee of individual reading accuracy, especially when comparing devices tested under different protocols or patient conditions.

2.2 How Is Pulse Oximeter Accuracy Evaluated?

Pulse oximeter performance studies may compare non-invasive SpO₂ readings with arterial oxygen saturation measurements obtained using a laboratory CO-oximeter.

A controlled desaturation study can evaluate device performance across a defined saturation range. Researchers collect paired measurements under specified conditions and calculate accuracy metrics from the resulting data.

According to the K232989 Summary, the referenced clinical study involved 11 healthy adult volunteers aged 21–47, with skin tones spanning Fitzpatrick types II–VI. The study evaluated performance under stationary conditions across the 70%–100% saturation range.

The summary states that the study data came from K221039 rather than describing a new clinical study conducted specifically for K232989.

For procurement teams, this distinction matters. The reported result provides evidence relevant to the device’s performance, but buyers should review the complete available study documentation and test conditions before applying the result to a new patient population or use case.

2.3 What the Accuracy Metric Does Not Establish

The reported (A_{RMS}<2) result should not be interpreted as proof that the device:

• Maintains the same accuracy during patient movement.

• Performs equally well under low peripheral perfusion.

• Delivers identical performance across every patient population.

• Is suitable for continuous monitoring or alarm-based clinical workflows.

• Guarantees a specific pulse rate accuracy across every possible heart rate.

These capabilities require appropriate supporting evidence and must be consistent with the actual device specifications and cleared intended use.

For an RPM deployment, the most useful approach is to compare the device’s documented performance with the operating conditions expected in the target patient population.

3. Intended Use: Why Motion and Low Perfusion Matter

A device’s intended use defines the context in which its performance claims should be evaluated. Even when two pulse oximeters measure SpO₂ and pulse rate, they may differ in their intended monitoring mode, supported patient population, and validated operating conditions.

The K232989 indications for use specify spot-checking of oxygen saturation and pulse rate using the finger of adult patients in home and healthcare environments. The document also states that the device is not intended for use under motion or low-perfusion scenarios.

3.1 Spot-Checking vs. Continuous Monitoring

Spot-checking involves taking measurements at selected times. Continuous monitoring involves tracking measurements over time and may require additional functions, such as alarms, signal-quality indicators, and documented performance under the intended monitoring conditions.

The K232989 Summary identifies the device as a spot-check pulse oximeter without alarms. It also states that the device is not intended for life-supporting or life-sustaining use.

Consequently, procurement teams should not assume that a spot-check model is interchangeable with a continuous-monitoring device simply because both display SpO₂ and pulse rate.

If a healthcare program requires continuous monitoring, buyers should identify a device whose cleared intended use and documented features support that workflow.

3.2 Understanding Low-Perfusion Limitations

Low peripheral perfusion can reduce the pulsatile signal available to a pulse oximeter. This can occur in circumstances involving reduced peripheral blood flow or other physiological and environmental factors.

When the signal becomes weak, measurement performance may be affected. However, the degree of impact depends on the device’s sensor design, signal-processing algorithms, and validated operating conditions.

Because K232989 excludes low-perfusion scenarios, buyers should not assume that the cleared models are suitable for patients who require measurements under those conditions.

For patient groups with known low-perfusion requirements, procurement teams should request evidence for the specific model and use conditions under consideration.

3.3 Matching Device Limitations to RPM Workflows

Use the following framework to evaluate whether a pulse oximeter fits a proposed deployment.

This assessment helps prevent a common procurement mistake: selecting a device based on a headline accuracy figure without checking whether its limitations fit the real-world application.

4. Three Essential Compliance Checks Before Buying a Pulse Oximeter

For B2B procurement, regulatory verification should be part of a broader technical and operational assessment.

Check 1: Verify the FDA Record and Exact Model

Start with the official K232989 database entry and its 510(k) Summary.

Confirm the manufacturer, model designation, product code, decision status, and indications for use.

Next, compare these details with the supplier’s quotation, product label, instructions for use, and technical datasheet. If the supplier offers a different model or a modified version, request documentation explaining the applicable regulatory status.

A clearance number associated with one model should not automatically be applied to every product offered by the same manufacturer.

Check 2: Review Performance Evidence and Test Conditions

Request the available performance documentation for the exact model being considered.

The review should cover:

• SpO₂ accuracy metrics and the saturation range evaluated.

• The applicable testing standard and test methodology.

• Clinical study conditions and reference measurement methods.

• Performance limitations under movement or low perfusion.

• Pulse rate specifications and their supporting evidence.

• Any differences between the tested configuration and the offered product.

For K232989, the FDA Summary references ISO 80601-2-61 bench testing and clinical accuracy data from K221039. Buyers should distinguish these documented facts from additional performance claims made in marketing materials.

Check 3: Assess Operational Fit and Integration Requirements

A regulatory clearance alone does not establish that a device will integrate smoothly into an RPM program.

Before placing an order, assess the intended patient population, measurement frequency, connectivity requirements, data transfer process, maintenance needs, and customer support arrangements.

For models with wireless functionality, verify the exact model’s connectivity options. The K232989 Summary identifies AOJ-70B and AOJ-70D as the models with Bluetooth connectivity.

Also confirm whether the deployment requires an application, a cloud platform, a particular data format, or integration with an existing remote monitoring system. These requirements should be evaluated separately from the FDA clearance itself.

5. B2B Procurement FAQs About FDA 510(k) K232989

Q1: Is FDA 510(k) K232989 the same as FDA approval?

No. K232989 received a Substantial Equivalence determination through the 510(k) pathway. It is more precise to describe the device as FDA-cleared through 510(k), rather than FDA-approved through PMA.

Q2: Does K232989 guarantee ±2% accuracy for every SpO₂ reading?

No. The summary reports (A_{RMS}<2) across the 70%–100% saturation range under steady-state conditions, based on clinical data referenced from K221039. This is an aggregate accuracy metric, not a guarantee that every reading falls within ±2 percentage points.

Q3: Can the K232989 pulse oximeters be used for continuous patient monitoring?

The K232989 Summary identifies the devices as spot-check pulse oximeters without alarms. Buyers should not assume they are suitable for continuous monitoring. Any alternative use must be evaluated against the applicable labeling and supporting evidence.

Q4: Are the devices suitable for patients with low peripheral perfusion?

The stated indications for use exclude low-perfusion scenarios. If a program requires measurements under low-perfusion conditions, buyers should evaluate devices with appropriate supporting evidence and indications for the intended use.

Q5: Does the clearance cover every AOJ pulse oximeter model?

The K232989 record lists five models: AOJ-70A, AOJ-70B, AOJ-70C, AOJ-70D, and AOJ-70E. Buyers should verify the exact model and confirm that any alternative or modified product has the appropriate regulatory documentation.

Q6: What documents should a distributor request before purchasing?

At a minimum, request the applicable FDA clearance record, 510(k) Summary, product labeling, instructions for use, technical specifications, and relevant performance test documentation. For RPM integration, also confirm connectivity, software compatibility, data handling, warranty terms, and after-sales support.

6. Source FDA-Cleared Pulse Oximeters for Your RPM Program

Selecting a pulse oximeter for an RPM program requires more than checking a regulatory number or comparing headline accuracy figures. Buyers should evaluate the FDA-cleared intended use, documented performance conditions, model-specific features, and integration requirements together.

For distributors, healthcare organizations, and remote monitoring solution providers, a structured verification process helps identify devices that better match the intended application and reduces the risk of unsupported performance assumptions.

Before finalizing a sourcing decision, request the relevant regulatory documents, performance specifications, and model-specific technical information from your supplier.

Contact our medical device team to discuss your pulse oximeter sourcing requirements, model specifications, connectivity options, and OEM or wholesale needs. Our team can help you identify the documentation required for a more informed procurement review.